CN Mobile Logo

Search form


Renal Cell Carcinoma

Renal Cell Carcinoma

The FDA announced a modification to the recommended dosage regimen for nivolumab (Opdivo) for renal cell carcinoma (RCC), metastatic melanoma, and non–small-cell lung cancer (NSCLC).

Patients with metastatic RCC and a BMI of 25 or greater had significantly longer overall survival compared with patients with a BMI of less than 25, according to the results of a recent study.

The combination of bevacizumab and everolimus had efficacy in patients with unclassified non–clear cell renal cell carcinoma characterized by papillary features, resulting in an objective response rate of 43%.

Effectively, the field has tested agents for metastatic disease in only two clinical settings: primary management of metastatic disease (first-line) and after progression with a first-line therapy (second-line); however, there are no category 1 data that support the use of any agent in the third-line setting.

Patients with RCC who underwent simultaneous nephrectomy and hepatic resection had similar postoperative mortality, long-term survival, and cancer-specific survival as those patients who underwent metastasectomy or en bloc resection of neighboring non-hepatic organs.

Although the overall incidence of programmed cell death 1 (PD-1) inhibitor-related pneumonitis is rare, the serious adverse event may occur more commonly in certain solid tumor types like non–small-cell lung cancer and renal cell carcinoma.

Patients with kidney cancer who are considered to be in poor functional health were less likely to receive cancer-directed surgery to treat their disease.


Subscribe to Renal Cell Carcinoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.